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Abstract The reduced muscle mass and impaired muscle
performance that define sarcopenia in older individuals are
associated with increased risk of physical limitation and a
variety of chronic diseases. They may also contribute to
clinical frailty. A gradual erosion of quality of life (QoL)
has been evidenced in these individuals, although much of
this research has been done using generic QoL instruments,
particularly the SF-36, which may not be ideal in older
populations with significant comorbidities. This review and
report of an expert meeting presents the current definitions
of these geriatric syndromes (sarcopenia and frailty). It
then briefly summarizes QoL concepts and specificities in
older populations and examines the relevant domains of
QoL and what is known concerning QoL decline with these
conditions. It calls for a clearer definition of the construct
of disability, argues that a disease-specific QoL instrument
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for sarcopenia/frailty would be an asset for future research,
and discusses whether there are available and validated
components that could be used to this end and whether the
psychometric properties of these instruments are suffi-
ciently tested. It calls also for an approach using utility
weighting to provide some cost estimates and suggests that
a time trade-off study could be appropriate.
Keywords Age  Aging  Muscle weakness 
Quality of life  Malnutrition
Introduction
The term ‘‘sarcopenia’’ helped to spotlight this common
muscle wasting condition when it was introduced in 1989
[1]. Since then, its definition has seen a number of modi-
fications, moving from a biogerontological concept to a
clinical condition, which focuses more on the pronounced
muscular deficits that impact functional independence and
the possible roles of extrinsic factors, such as lifestyle,
nutrition, and concomitant disease [2]. In 2010, two articles
were published, and a third the following year, that pro-
posed consensus diagnosis criteria [3–5]. Their conclusions
were similar and should serve as a base for future research.
The term ‘‘frailty’’ represents a well-recognized clinical
syndrome, yet it is defined by a number of different clas-
sification criteria [6, 7]. A key element underlying most
frailty definitions is sarcopenia (i.e., skeletal muscle loss)
[7, 8]. Frail older people are particularly vulnerable to
external stressors and less able to resist the mental and
physical challenges after a destabilizing event, although it
is now clear that both frailty and sarcopenia carry a prog-
nosis of (rapid) further functional decline with a higher risk
of comorbidity and increasing disability (higher risks of
falls, hospitalization, institutionalization, and death) than in
the older population as a whole [9–11]. Thus, one of the
major challenges of geriatric medicine is to recognize these
conditions as soon as possible and to halt (or slow)
the downward spiral of increasing comorbidity and frailty
[7, 12].
That the quality of life (QoL) declines in frailty is
intuitively evident, and there are good indications that this
is also the case for sarcopenia. However, in the absence of
specific QoL tools and without a clear conceptual frame-
work of QoL in these patients, an important element in the
characterization and follow-up of these conditions seems to
be missing. Since comorbidities are very frequent in both,
attributing QoL to the core condition remains a challenge.
We describe herein the conclusions that were made
during a discussion session in November 2012 on a pos-
sible QoL assessment in sarcopenia and frailty.
Definitions
Sarcopenia
The three consensus papers which have published a defi-
nition of sarcopenia were written under the auspices of,
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respectively, the European Working Group on Sarcopenia
in Older People (EWGSOP) [3], the European Society for
Clinical Nutrition and Metabolism Special Interest Groups
(ESPEN-SIG) [4], and the International Working Group on
Sarcopenia (IWGS) [5]. The consensus definitions were as
follows:
• The presence of low skeletal muscle mass and either
low muscle strength (e.g., handgrip) or low muscle
performance (e.g., walking speed or muscle power);
when all three conditions are present, severe sarcopenia
may be diagnosed (EWGSOP).
• The presence of low skeletal muscle mass and low
muscle strength (which they advised could be assessed
by walking speed) (ESPEN-SIG).
• The presence of low skeletal muscle mass and low
muscle function (which they advised could be assessed
by walking speed) and ‘‘that [sarcopenia] is associated
with muscle mass loss alone or in conjunction with
increased fat mass’’ (IWGS).
Thus, the EWGSOP consensus, by separating muscle
strength and muscle performance, allows for a slightly
broader definition and provides a classification of a severe
condition.
A fairly long-running debate in this field is whether or
not to apply the term ‘‘dynapenia’’ to the age-related loss of
muscle strength and limiting sarcopenia to age-related loss
of muscle mass [13]. Although the two processes may
occur simultaneously in some individuals, they do not
necessarily overlap and may be the result of different
pathophysiological processes. The EWGSOP consensus
authors, however, seem to be of the opinion that since
‘‘sarcopenia’’ is already a fairly well-known term, the
introduction of another may lead to confusion [3].
The EWGSOP consensus also discussed the frailty
concept and its overlap with sarcopenia. It recognized, as
others have done [6, 14], that frailty is characterized by
deficits in multiple organ systems, i.e., psychological,
cognitive, and/or social functioning, as well as physical
limitations.
Frailty
While a theoretical definition of ‘‘frailty’’ could be the lack
of functional reserve [15], no single operational definition
has met with widespread acceptance and consensus meet-
ings have yet to offer a solution [6, 16]. Widely used
operational (phenotypic) definitions are those suggested by
Rockwood and colleagues in 1999 [17] and Fried and
colleagues in 2001 [18]. The Rockwood definition, with
four classes of disability, is considered by some experts in
the field to be flawed by using a combination of frailty and
disability and considering frailty as a risk factor for dis-
ability. The Fried definition cites the accumulation of
deficits in five domains: unintended weight loss, muscle
weakness (grip strength), self-reported exhaustion, slow
walking speed (i.e., low gait speed), and low physical
activity. A total of two deficits indicates a prefrail condi-
tion, and a total of three or more deficits indicates frailty.
More recent frailty scales have been proposed, and some of
these use continuous variables [19] or extend the scale with
social and psychological measures [20–22]. The majority
of definitions of frailty include loss of skeletal muscle as a
component [8], and it is the musculoskeletal component of
frailty as the phenotype that most frequently comes to the
attention of health-care professionals [6].
Sarcopenic Obesity
The term ‘‘sarcopenic obesity’’ has been used to describe a
subgroup of sarcopenic individuals with a high percentage
of body fat. This subgroup has been recognized for some
time as having a particularly high risk of adverse outcomes
[23]. The condition is characterized by, in addition to low
lean muscle mass or low muscle performance, excess
energy intake, low physical activity, low-grade inflamma-
tion, and insulin resistance [3, 23].
Cachexia
This describes a severe wasting condition that is seen in
chronic disease states such as cancer, congestive cardio-
myopathy, and end-stage renal disease. This was the sub-
ject of the ESPEN-SIG consensus report [4], and the
definitions presented therein and previously [24] were
endorsed by the EWGSOP. Cachexia is associated with
inflammation and frequently with insulin resistance and
anorexia. It may therefore be viewed as a complex meta-
bolic syndrome invoked by the underlying illness. While
most cachectic individuals also have sarcopenia; sarcope-
nic individuals, unless they have an increased inflammatory
status and/or impaired carbohydrate, protein, or lipid
metabolism, are not considered as having cachexia.
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Diagnostic Criteria
Sarcopenia
The consensus papers concurred on the use of a T-Score–
based cutoff for lean (skeletal) muscle mass (appendicular
lean mass [aLM]) divided by height squared with a
threshold of C2 standard deviations (SD) below the mean
measured in young adults in a reference population. The
EWGSOP suggested that muscle mass could be determined
by computed tomography (CT scan) or magnetic resonance
imaging (MRI, the gold standards) or dual-energy X-ray
absorptiometry (DXA, the preferred alternative); the IWGS
pronounced for DXA; and the ESPEN-SIG gave no indi-
cation. Using the Rosetta study for the reference population
[25] and using DXA for mass measurement, this
T-Score method gives values of B7.3 kg/m2 for men and
B5.5 kg/m2 for women.
It seems relevant, however, that aLM is also indexed for
body fat mass (e.g., on the residuals from a regression
analysis). This approach, used in the Health, Aging, and
Body Composition (Health ABC) study [26], was found to
give a better identification of overweight or obese sarco-
penic individuals and better associations with impaired
lower extremity function. Other recent research investiga-
tions, which have used DXA to measure body tissue mass,
applied a definition of obesity as body fat mass greater than
the 60th percentile of a ‘‘normal’’ population (typically
28 % body fat in men and 40 % in women) [27, 28].
The second criterion for sarcopenia in all three con-
sensus papers was usual gait speed. The most favored
assessment seems to be on a 4 m course, with a reference
speed of either 0.8 m/s (suggested by EWGSOP and
ESPEN-SIG) or 1 m/s (IWGS), where the inferior values
are indicative of sarcopenia. Further research will be
required to more closely define this threshold, with perhaps
a small difference between genders. In a recent cross-sec-
tional study [29] of 3,145 older adults in England (aged
C65 years, 46 % men) it was found that the mean walking
speed was 0.9 m/s in men and 0.8 m/s in women. The
conclusion of this study, which examined walking speed in
the context of traffic collisions and socioeconomic factors,
was that the national standard of normal walking speed for
pedestrian crossings of 1.2 m/s was too high for this seg-
ment of the population.
A third criterion (suggested by the EWGSOP) was low
muscle strength, which, it was suggested, can be most
conveniently measured using a handgrip dynamometer
(with a certain preference for the Jamar model).
Table 1 gives the cutoffs for the more widely used and
well-validated criteria for lean muscle mass determined by
DXA, muscle strength, and muscle performance by gait
speed.
Frailty
Using the definition of ‘‘frailty’’ proposed by Fried, there
remains heterogeneity of assessment methods and of the
cutoff values for a positive diagnosis. Table 2 shows a
small sample of trials that have analyzed their respective
populations according to these criteria; the reference study
by Fried appears in the first column. It may be seen that a
number of more or less subtle differences are evident, from
the methods of correction of parameters for body size or
gender to the use of subjective reports in place of objective
measurements. In the examples shown, the percentages of
frail and prefrail individuals show some similarities despite
the methodological differences (4–11 % for frail and
37–55 % for prefrail). Others have found, however, quite
heterogeneous results when different frailty criteria are
applied, with the prevalence in a sample population rang-
ing 33–88 % [33].
The Need for Simplicity and Consistency
in Measurement and Terminology
The EWGSOP consensus paper interestingly provides
details and suggested threshold values for a number of
other measurement techniques, which do provide valid
performance assessments. Some are more widely used,
such as short physical performance battery (SPPB) and the
‘‘timed get-up-and-go’’ (TGUG) protocol; others are less
so. Here, and elsewhere in the literature, it can be seen that
various methodological debates exist, such as whether
muscle power as a measure provides greater prognostic
value than muscle strength, whether grip strength is better
assessed on the dominant hand or the nondominant hand,
and whether the recorded value should be the best of three
tries, meaned, or summed [38, 39].
Table 1 Frequently used cutoff values for a selection of diagnostic
criteria for sarcopenia
Men Women
Skeletal muscle mass
SMI by DXA [25] \7.26 kg/m2 \5.45 kg/m2
Muscle strength
Handgrip strength [30] \30 kg \20 kg
Muscle performance
Gait speed on 4 m course [31] \1.0 m/s
SPPB [32] B8
DXA dual-energy X-ray absorptiometry, SMI skeletal muscle mass
index, where appendicular skeletal muscle mass is standardized using
the square of the individuals’ height; SPPB short physical perfor-
mance battery, summation of scores for balance, gait speed, and chair
stand (max score = 12)
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From the premise that one should proceed from simpler
theories only when simplicity can be traded for greater
explanatory power, it might be argued that, with the
application of the criteria and threshold values from the
consensus statements, it would be judicious to keep the
methodologies and assumptions as simple as possible so as
to test prognostic theories.
Efforts must also be made toward consistency of
terminology and clarity of definitions. This is required
for the terminology associated with muscle contraction,
e.g., ‘‘performance,’’ ‘‘function,’’ ‘‘strength,’’ ‘‘quality,’’
‘‘endurance,’’ as well as the terminology for disability and
QoL concepts. A laudable plea for a common language for
disablement research was made previously by Jette [40],
who recommended using the language and concepts of the
International Classification of Functioning, Disability and
Health (ICF) framework of the World Health Organisation
(WHO) [41].
Etiology
The underlying causes of sarcopenia and frailty are mul-
tifactorial. Although the progressive loss of muscle mass
with aging has been recognized for a long time, it is only
with more recent techniques and longitudinal prospective
studies that the age-related changes in body composition
have begun to be described [42–45]. The main processes
involved in the maintenance of muscle tissue and the
decline toward sarcopenia are summarized in Fig. 1.
Muscle, given its usual environment of biomechanical
attachment, neural inputs, and energy supply, can be
considered as having a number of positive and negative
regulators that influence its maintenance and ‘‘health’’ [46,
47]. Thus, muscle tissue is negatively impacted when the
influence of positive regulators is diminished (e.g., low
vitamin D status) [48, 49] and when negative regulators are
augmented (e.g., inflammatory conditions) [50]. Muscle
mass is increased by physical activity and protein intake
[51]. Muscle strength is increased (in all age groups) by
physical activity [52].
The process of normal aging, with the changes in hor-
monal status (e.g., following menopause or andropause)
[53, 54], with the onset of anabolic resistance [55], and
with a more sedentary lifestyle, leads to loss of muscle
mass and muscle strength [44, 56]. With the concerted
influence of other factors, such as obesity and chronic low-
grade inflammation [57], muscle loss is enhanced. This is
then further exacerbated by feedback systems that are ini-
tiated in the muscle tissue. An increase in intramuscular fat
at this stage is associated with an accelerated decline in
muscle quality (strength per unit of mass) [58]. Another
factor to be taken into consideration in older persons is the
negative impact on muscle tissue of polymedication.
Treatments for Sarcopenia and Frailty
The risk factors for sarcopenia, in addition to low physical
activity and poor nutrition, include chronic inflammation
and obesity and, thus, are to some extent modifiable.
The first step to be taken for a person with sarcopenia or
clinical frailty is to ensure that he or she is receiving cor-
rect and sufficient nutrition [59]. An insufficient diet is
Fig. 1 The control of muscle
maintenance and the decline to
sarcopenia. It is assumed that
the muscle is in its usual
environment of biomechanical
attachment, neural input. and
energy supply. GH growth
hormone, IGF-1 insulin-like
growth factor 1, HGF
hepatocyte growth factor, FGF
fibroblast growth factor
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quite frequent in older people [55, 60]: in a recent study of
hip fracture patients admitted to hospitals in Sydney,
Australia, 58 % were found to be undernourished and 55 %
had a vitamin D deficiency [61]. Nutritional assessment
may be made by one of a variety of questionnaires
including the nutritional risk screening (NRS-2000), the
simplified nutritional appetite questionnaire (SNAQ), the
malnutrition universal screening tool (MUST), the mini
nutritional assessment (MNA), and the SNAQ65 ? (the
two latter instruments have been tested in or developed for
older persons [62, 63]).
It is also important that the sarcopenic/frail individual
should be given minimal physical activity and if possible
resistance training [52, 64, 65]. Pharmacological treatments
remain, for the moment, research projects [66]. The posi-
tive effect of inhibiting angiotensin II converting enzyme is
currently undergoing clinical trials, as are blockers of
chronic inflammation. Trials of hormone treatments have
shown either complications or no proof of efficacy, while
trials of myostatin inhibitors are ongoing.
Functional Consequences Associated with Sarcopenia
and Frailty
Low Muscle Performance or Strength Has Prognostic
Implications
In the 1990s a number of research studies in healthy older
populations began observing that low muscle performance
was associated with a higher risk of future disability. For
example, in a key prospective study conducted by Guralnik
and colleagues [67] in [70-year-old community-dwelling
individuals, participants were assessed by the SPPB at
baseline and then followed up by interview 4 years later.
Those with lower baseline scores were associated with
higher levels of disability (activity- and mobility-related) at
follow-up. After adjustment for age, sex, and the presence
of chronic disease, those with the lowest SPPB scores (4–6)
were four times more likely to have disability at follow-up
than those with the highest scores (10–12). This was later
confirmed in a large-scale, multi cohort study which also
noted that gait speed alone had almost the same prognostic
ability as the complete SPPB [32].
Early in the following decade, the landmark study
known as the Health ABC trial clearly demonstrated that
the loss in muscle strength over time was greater than the
loss of muscle mass (particularly the loss of fast-twitch
muscle fiber). This study, which followed 1,880 older
adults over 3 years, found annualized rates of decline in leg
strength of 3.4 % in men and 2.6 % in women, whereas the
rates of loss of leg lean mass were only about 1 % per year
[68].
Subsequent mobility limitations of those enrolled in the
Health ABC study were developed by 22.3 % of men and
by 31.8 % of women. This loss in mobility was associated
with lower muscle mass, lower muscle strength, and
greater muscle tissue attenuation (a measure of fat infil-
tration), when analyzed using a Cox’s proportional hazards
model to compare the lowest quartiles to the highest in
each criterion and adjusting for demographic, lifestyle, and
health factors. But when all three muscle criteria were
included in a single regression model, only lower muscle
strength and greater muscle tissue attenuation were inde-
pendently associated with incident mobility limitation
(p \ 0.05) [69].
The association of body fat and physical limitation was
shown at about the same period in the EPIDOS (Epide-
miologie de l’Osteoporose) study, a cross-sectional
investigation of older women with osteoporosis [28]. The
study showed that in obese women low muscle mass was
associated with an increased risk of physical limitation.
But in nonobese women this association was not apparent.
Thus, it would appear that low muscle strength and poor
muscle quality (i.e., increasing fat infiltration) are strong
indicators of functional decline, whereas low muscle mass
is not.
Absolute Muscle Strength is a Prognostic Indicator
of Functional Decline
Remarkably, it would also appear that absolute muscle
strength at a point in time is a good long-term indicator of
functional outcome. In a 25 year prospective cohort study in
healthy men 45–68 years old, maximal handgrip strength
was assessed at baseline [70]. Of the 6,089 individuals
enrolled, 2,259 died over the follow-up period and 3,218
survivors (53 %) participated in the follow-up disability
assessment 25 years later. Those with the lowest tertile on
grip strength at study entry were associated with a very low
walking speed (\0.4 m/s) (odds ratio [OR] = 2.87) and a
twofold greater risk of self-care disability. These associa-
tions persisted after adjustment for multiple potential con-
founders including chronic conditions.
This result was recently corroborated by the Invecchiare
in Chianti (InChianti) study [71], which measured grip
strength, knee extension strength, and lower extremity
power at baseline and mobility function (gait speed and
self-reported mobility disability) in 934 adults aged
C65 years. At the end of 3 years of follow-up, men who
had low leg power (\105 W) at baseline were associated
with a ninefold increase in mobility disability; low knee
extension strength (\19.2 kg) and grip strength (\39.0 kg)
were associated with relevant reductions in gait speed.
While these associations were particularly strong in men,
they showed similar trends in women.
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In another cross-sectional study of 2,208 subjects (aged
55 and older), low handgrip strength and walking limitation
(\1.2 m/s or difficulty walking 500 m) were correlated
with increased body fat [72]. The researchers found that the
prevalence of walking limitation was much higher in per-
sons who simultaneously had a high body fat percentage
and low handgrip strength (61 %) than in those with a
combination of low body fat percentage and high handgrip
strength (7 %).
Obesity Increases the Risk of Functional Decline
in Frail Older Persons
As mentioned above, there appears to be a particularly high
risk of functional decline when frailty is concomitant with
obesity.
In the cross-sectional Women’s Health and Aging studies
I and II [73], 599 community-dwelling women (aged 70–79,
BMI [ 18.5 kg/m2) were classified for frailty status (Fried
criteria). The multinomial regression model returned a sig-
nificant association for obesity and frailty (OR = 3.52,
95 % confidence interval [CI] 1.34–9.13), as well as obesity
and prefrailty (OR = 2.23, 95 % CI 1.29–3.84).
Comorbidities Associated with Sarcopenia and Frailty:
Impact on Quality of Life
It seems, therefore, that sarcopenia and frailty increase the
risk of physical limitation and subsequent disability; but
recent research also shows that these conditions increase
the risk of comorbid conditions.
In a systematic review and meta-analysis of published
(prospective) studies that had assessed physical capability
(using measures such as grip strength, walking speed, chair
rises, and standing balance) and subsequent outcome
(including fracture, cognition, cardiovascular disease,
hospitalization, and institutionalization), Cooper and col-
leagues [74] found that those who demonstrated lower
physical capability had a higher risk of negative outcomes.
To be included in the analysis, all papers had to identify in
their respective populations the possible confounders of the
association to be studied and a description of the methods
used to control for them. A few of the results in the four
main categories are presented below:
Fracture risk: in seven out of nine study samples,
researchers reported that lower grip strength was asso-
ciated with a higher subsequent fracture risk; and in four
out of five study samples, low walking speed was
associated with a higher fracture risk.
Cognitive function: in three study samples that examined
grip strength and cognitive function, all found that low
strength was associated with a higher subsequent risk of
cognitive decline and development of Alzheimer’s
disease or other forms of dementia. (Also in this context,
it is interesting to note that gait analysis in older people
is indicative of their cognitive profile [75].)
Cardiovascular outcomes: in three study samples that
examined grip strength and cardiovascular outcomes,
one found that low strength was associated with
increased risk of coronary heart disease over the
subsequent 24 years, one found that low strength was
associated with higher levels of fasting insulin, and the
third (in women) found no association between strength
and risk of stroke.
Hospitalization: in two out of three study samples, low
walking speed was found to be associated with an
increased risk of hospitalization. Additional data cor-
roborate the association between muscle strength
and hospitalization outcomes. In a small prospective
cohort study of older patients (n = 120, age range
75–101 years), Kerr and colleagues [76] investigated the
association between grip strength and hospitalization
outcome. Using a Cox proportional hazards model, they
found that higher grip strength on admission was
associated with increased likelihood of discharge to
usual residence. A grip strength of [18 kg for women
and 31 kg for men was associated with a 25 % increase
in the likelihood of return home. Others have found that
low muscle strength or performance (but not muscle
mass) was associated with the risk of hospitalization
[77].
Low physical capability is also associated with addi-
tional comorbidities such as diabetes and risk of falling as
well as increased risk of death.
• Diabetic men (previously or newly diagnosed), in the
Hertfordshire cohort [78], had significantly weaker
muscle strength and higher odds of impaired physical
function than those without diabetes. This relationship
held up also for individuals with impaired glucose
tolerance and right across the normal range of glucose
concentration. In women, the effect sizes were smaller
and less consistent, perhaps reflecting sex differences in
body composition. Subsequently, it has been shown that
diabetes is associated with an accelerated loss of
muscle mass and muscle strength [79, 80].
• The risk of falls is greatest in individuals with low
muscle strength. The guideline published by learned
geriatric societies for the prevention of falls in older
persons [81] put muscle weakness as the strongest risk
factor, more than a history of falls or gait or balance
deficits. The older men enrolled in the MrOS study
(n = 10,998) who had a handgrip strength score[2 SD
below the reference mean had a 2.4-fold higher risk of
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recurrent falls (95 % CI 1.7–3.4) than older men of
‘‘normal’’ strength [82].
• Mortality risk, after adjustment for demographics,
health behaviors, comorbidity, and cardiovascular dis-
ease risk factors, is higher in older people with low
physical capability. As part of the Health ABC Study,
3,075 community-dwelling adults (aged 70–79 years,
52 % women) were asked to perform a 400 m walk test
at baseline and the results were correlated with outcome
after 5 years (total mortality, incident cardiovascular
disease, incident mobility limitation, and mobility
disability) [83]. Among those able to complete the test,
each additional minute of performance time was
associated with an adjusted hazard ratio (HR) of 1.29
(95 % CI 1.12–1.48) for mortality (statistically signif-
icant worsening was also seen for the other outcome
measures). The crude mortality rate in the poorest
quartile for the walk test was 39.9 per 1,000 person-
years versus 14.2 per 1,000 in the best quartile
(adjusted HR = 3.23, 95 % CI 2.11–4.94; p \ 0.001).
Similar correlations have been made between frailty and
comorbidities [84]. Thus, while it seems that both of these
geriatric conditions increase the risk of comorbidity, it is
also evident that a number of comorbid conditions increase
the risk of sarcopenia and/or frailty. In consequence, the
patient enters into a vicious circle of further functional
decline.
The QoL Instruments Used in Older Populations
and Relevant Disease States
Why Study QoL?
Health-related QoL (HR-QoL) has been defined as ‘‘a
subjective measure which is evaluable over time and hav-
ing a focus on the qualitative dimension of functioning,’’
i.e., an assessment of functional status, physical, mental,
and social subjective dimensions that might provide evi-
dence over time of the impact on the individual in terms of
health status, satisfaction, and contentment in everyday
life. These assessments are important for governments and
health-care providers to understand the needs and preoc-
cupations of important segments of the population, allocate
resources, and define health-care reforms and initiatives
accordingly. Increasingly, their concern focuses on the
robustness of outcomes in relation to both the inputs and
processes of health-care delivery. Since the interest is in
subjective measures, the instruments are frequently refer-
red to as patient-reported outcomes (PROs), i.e., any report
of the patients’ health condition that comes directly from
the patient, without interpretation of the patients’ response
by a clinician or anyone else.
For complete assessment of the benefits of an inter-
vention it is essential to provide evidence of the impact on
the patient in terms of health status and HR-QoL. Such an
approach is also essential in a comprehensive global
assessment of older people [85] and should be taken into
account in guided treatment decisions of any chronic
illness.
Even in the assessment of physical functioning, the
evidence suggests that self-reported and performance-
based data may provide different and complementary
information. This was the conclusion of a recent study in
hip fracture patients [86], in which the responsiveness of
self-reported measures (five-point Likert scales and Euro-
QoL 5D) was compared with performance-based measures
(including knee-extensor strength, the PPME [physical
performance and mobility examination], chair-rise test, and
maximum balance range). The researchers found that
the correlations between the two approaches were only
small to medium. Walking speed and chair-rise test were
among the most responsive performance-based measures;
the self-reported measures often indicated greater levels of
disability.
There are numerous different concepts of QoL, ranging
from psychological perspectives, ‘‘utilities’’ and the trade-
offs that individuals make, to the reintegration to normal
living [87]. This fact and the implicit value of having a
subjective measure of welfare have resulted in a multitude
of QoL instruments [88]. Two distinctive classes of
instruments exist to assess HR-QoL. Generic instruments
are designed to be applicable across a wide range of pop-
ulations, diseases, and interventions, whereas specific
instruments are relevant to particular subpopulations or
illnesses. While this review is not the place to discuss all
the aspects of the QoL assessments, it seems pertinent to
recall a few salient points.
Concepts and Specificities
It is usually considered that there are three broad dimen-
sions in the HR-QoL construct: physical/occupational
function, social health/integration, and mental health/psy-
chological state, while the non-health-related QoL includes
financial and economic aspects, spiritual and political
aspects, and environmental factors [87].
For any study of QoL, it is important that a conceptual
framework of the QoL dimensions and subordinate domains
be made [89], describing how the assessment scales relate to
the studied population and to the proposed risk factor(s) of
interest. This is a step that is unfortunately omitted from
many research publications, hindering their comparative
evaluation [90, 91]. QoL instruments should also clearly
define the recall period to which patients/individuals are
meant to refer. While a number of questionnaires do preface
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the question blocks by ‘‘in the last week’’ or ‘‘in the last
month,’’ this is not systematic and the recall periods vary
considerably between instruments.
A subtle aspect of QoL studies in patients with chronic
disease (or for that matter following a serious illness or
intervention) is that of ‘‘response shift’’ or adaptation, i.e.,
a change in perspective of QoL accounting for actual
physical condition [92]. Studies have found that older
people tended to compare themselves with their peers and
that the mildly frail identified themselves with those worse
off and the most frail identified themselves with those
doing better [85, 93]. A potential solution to this might be
the use of a visual analog scale relating actual well-being
with the best and worst periods in the subject’s life [94,
95], i.e., a single question which may anchor subsequent
questionnaires.
The length of questionnaires is highly variable, and
there is clearly a trade-off between short forms (with
acceptable imprecision and high completion rates) and long
forms (with greater precision and lower completion rates).
Thus, there is a risk that specific QoL instruments become
long and onerous to complete [96]. A contemporary
approach to this response burden is computer-assisted
adaptive testing, which, as an example of a questionnaire
assessing disability outcomes, reduced the completion time
from 20–30 minutes to 3.56 minutes without loss of mea-
surement accuracy, precision, or reliability [96].
In pharmacoeconomic studies, the utilities (preferences)
for a health condition need to be established, which are
then usually used to calculate quality-adjusted life years.
Frequently this is done using a validated QoL questionnaire
(such as the EQ-5D), but in any new area, the assumptions
should be verified using another method. For example, in
the study by Salkeld and colleagues [97] in hip fracture
patients, this was done using the time trade-off technique.
Patients (194 women aged 75–98 years) were asked to rank
different health states (‘‘full health,’’ ‘‘fear of falling,’’
‘‘good hip fracture,’’ and ‘‘bad hip fracture’’) and to trade
off shorter periods of full health with longer periods of
impaired health. The results showed that the women placed
very high marginal value on their health and that 80 %
would rather be dead than experience the loss of inde-
pendence and the poor QoL that results for a bad hip
fracture and subsequent admission to a nursing home.
Generic QoL Instruments
Generic QoL questionnaires are widely used since they
allow comparison of the burden of disease between dif-
ferent disease states. They carry risk, however, of being
relatively insensitive to any particular pathological condi-
tion; and therefore, changes over time or treatment may be
lost to background (low signal to noise).
‘‘Broad-use’’ generic QoL instruments (particularly the
SF-36) are popular in the study of older populations, and
several comparative reviews are available [98, 99]. It has
been argued, however, that the assessment of QoL in older
persons should use QoL instruments that are adapted to the
specificities of the age group [85, 100, 101] and differen-
tiate between people dwelling in the community and those
who are institutionalized [102]. These types of instruments
have been reviewed previously [100, 103, 104].
Table 3 presents a few of the more widely reported
‘‘broad-use’’ generic QoL instruments and some that have
been designed for older populations.
Given its widespread use, it is perhaps pertinent to
discuss briefly the characteristics of the SF-36. This
instrument was designed to satisfy minimum psychometric
standards in a very broad range of individuals (14 years old
or more) with the aim of surveying a general population for
health policy objectives [105]. The eight domains (or
health concepts) were selected from 40 that were included
in the Medical Outcomes Study (MOS) and considered to
be the most pertinent in most patients: physical function-
ing, physical roles, bodily pain, general health, mental
health, emotional roles, social functioning, and vitality.
While some of the scales of the SF-36 have been shown to
have 10–20 % less precision than the long-form MOS
measures they were constructed to represent, this weakness
is offset by the fact that the SF-36 has a 5- to 10-fold lower
response burden than the long-form questionnaire [112]. It
is recognized that the SF-36 functions best as a ‘‘generic
core’’ to compare populations across studies and that it
should be supplemented with disease-specific instruments
if it is to comprise a principal health outcome measure
[112]. The SF-36 has been found to be a simple and
effective measure of mobility-disability in epidemiological
studies [113], although a substantial ceiling effect for some
domains has been noted [114].
Specific Instruments
A large number of disease-specific QoL instruments exist
but none as yet specific for sarcopenia or frailty. QoL
instruments do, however, exist for certain other diseases
which may be of interest in defining impacted domains in
sarcopenia, either because they have a relatively high
prevalence in older people, such as osteoporosis and stable
angina, or because they have a significant effect on phys-
ical functioning, such as chronic obstructive pulmonary
disease and Parkinson’s disease.
Osteoporosis
Some of the QoL instruments that have been developed for
studies in osteoporosis are presented in Table 4. Three are
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self-administered questionnaires, and three are given by an
interviewer. The number of domains assessed varies from
two to seven and the number of questions, from 23 to 84.
Heart Disease
The impact of chronic cardiovascular disease on QoL has
been investigated in numerous studies, and several specific
instruments are available [88]. Studies of stable angina are
of potential interest since the patients are frequently older,
community-dwelling women. Of note are the HeartQoL
questionnaire and the Seattle Angina questionnaire.
Patients with heart failure are usually more severe, and
these specific instruments (e.g., the Minnesota living with
heart failure questionnaire and the Kansas City cardiomy-
opathy questionnaire) are of less interest.
Muscle Disease
The individualised neuromuscular QoL instrument
(INQOL) is a 45-item questionnaire designed for patients
with muscle diseases that examines the impact of symp-
toms (weakness, myotonia, pain, and fatigue), the effects
they have on aspects of daily life, and the positive and
negative effects of treatment [121].
Chronic obstructive Pulmonary Disease
The impact of this disease on QoL has been examined in
several studies, and a pertinent review is that by Gimeno-
Santos and colleagues [90].
Studies of QoL Assessment in Sarcopenic or Frail
Populations
Studies that assessed QoL in populations of older com-
munity-dwelling individuals with a diagnosis of either
sarcopenia or frailty are presented in Table 5. Of the eight
studies identified, five used the SF-36; the other instru-
ments were the OPQOL, the WHOQO-Bref, and the
quality of life systemic inventory questionnaire. In three of
the studies using the SF-36 (in frail patients), the mean
Table 3 Generic QoL instruments
Name Number of
questions
Domains (number of questions)
SF-36 36 8 Domains: general health (5), physical functioning (10), role limitation-
physical (4), mental health (5), role limitation-emotional (3), social
functioning (2), bodily pain (2), vitality (4)
MOS 36-item short form health survey [105]
EuroQol EQ-5D 5 5 Domains: anxiety/depression (1), mobility (1), pain/discomfort (1), self-
care (1), usual activities (1)European QoL questionnaire [106]
Nottingham health profile (NHP) [107] 38 6 Domains: bodily pain (8), emotional reactions (9), energy (3), physical
mobility (8), sleep (5), social isolation (5)
Instruments for older persons
OPQOL-brief 35 8 Domains: life overall (4), health (4), social relationships and
participation (5), independence, control over life and freedom (4), home
and neighborhood (4), psychological and emotional well-being (4),
financial circumstances (4), leisure, activities and religion (6)
Older people’s quality of life questionnaire
[100]
CASP-19 [108] 19 4 Domains: control, autonomy, self-realization, pleasure
PGC-MAI 147 (? mid-length
[68] ? short [24])
6 Domains: ADL (16), cognition (10), perceived environment (25),
personal adjustment (12), physical health (49), social interaction (17),
time use (18)
Philadelphia geriatrics center multilevel
assessment instrument [109]
PWB 14 2 Domains: psychological well-being (6), physical well-being (8)
Perceived well-being scale [109]
ACSA 14 1 Domain: subjective well-being—the ACSA asks the patient to
remember the best and worst periods of his or her life experience
(assigned ?5 and –5, respectively), then to rate current life satisfaction
(over period).
Anamnestic comparative self-assessment
scale [94]
LEIPAD [110] 49 7 Domains: cognitive function (5), depression/anxiety (4), life satisfaction
(6), physical function (5), self-care (6), sexual function (2), social
function (3) & other moderator scales (18)
WHOQoL-Old [111] 24 6 Domains: sensory abilities (4); autonomy (4); past, present, and future
activities (4); social participation (4); death and dying (4); intimacy (4)
ADL activities of daily living, IADL instrumental activities of daily living
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physical and mental summary values were presented; and
these show notable heterogeneity. Also apparent from these
three studies is that the SDs for the means in the robust,
prefrail, and frail groups equal or exceed the differences
between the groups. In this respect, the OPQOL scores
appear to show a more satisfactory result.
In the cross-sectional Hertfordshire cohort study [114],
in nearly 3,000 community-dwelling men and women aged
59–73 years, the relationships between grip strength and
HR-QoL using the SF-36 were investigated. The results
showed (using simple unadjusted analyses) that low grip
strength (in both men and women) was associated with
increased prevalence of having poor scores for all of the
domains of the SF-36 instrument. With adjustment for age,
height, weight, walking speed, social class, smoking,
alcohol consumption, and known comorbidity, lower grip
strength remained associated with a low physical func-
tioning score and a low general health score. These rela-
tionships were not explained by falls history. Thus, even
after adjusting for muscle performance (walking speed),
low muscle strength (handgrip) was associated with low
HR-QoL
Frailty is Associated with Poor QoL
Frail and prefrail individuals have lower QoL scores
compared to age- and comorbidity-matched nonfrail indi-
viduals. One relevant study in this context is the hispanic
established populations epidemiologic studies of the
elderly (Hispanic-EPESE), which enrolled 1,008 older
adults living in the community [122]. The results showed,
after adjusting for sociodemographic and health-related
covariables, that being prefrail or frail was significantly
associated (p \ 0.001) with lower scores on all physical
and cognitive HR-QoL scales than being nonfrail. Fur-
thermore, in a longitudinal study of 484 community-
dwelling persons 75 years and older frailty status was
assessed at baseline (Tilburg Frailty Indicator) and QoL
was assessed after 1 and 2 years (WHOQoL-BREF) [126].
The results revealed very large associations between frailty
status and poor QoL.
In older, frail nursing home residents it has been shown
that muscle fatigability (assessed by sustained grip
strength) was related to both self-perceived fatigue and
QoL (WHOQOL, Mobility-Tiredness scale, physical
domain score of SF-36) [128]. Since fatigue is often con-
sidered a key element in frailty, its estimation both
objectively and subjectively might help to distinguish the
muscular (related to sarcopenia) and mental components
affecting QoL in these patients.
Conclusions on QoL Research in Older Populations
What emerges from this research in older populations (and
mostly from generic QoL instruments or structured inter-
views) is that physical functioning plays an extremely
important role in QoL. The striking thing about this con-
clusion is the similarity to the drivers of QoL in patients
with chronic diseases [99].
The main drivers of QoL in older adults are, therefore,
energy, freedom from pain, ability to do activities of daily
living, and ability to move around [97, 101]. Those who
regularly do at least 1 h per week of moderately intense
physical activity had higher HR-QoL measures (on SF-36)
than those who do not [129]. They have a strong need, the
Table 4 QoL instruments for osteoporosis
Name Administration Number of questions Domains (questions)
Qualeffo-41 [115] Self-administration 41, short version: 31 7 Domains: pain (5), physical function-ADL (4),
physical function-IADL (5), physical function-
mobility (8), social function (7), general Health
perception (3), mental function (9)
QUALIOST (questionnaire QoL in
osteoporosis) [116]
Self-administration 23 2 domains: physical function, emotional status
OPAQ (osteoporosis assessment
questionnaire) [117]
Self-administration Version 1: 84
Version 2: 60
Version 3: 34
4 Domains: physical function, emotional status,
symptoms, social interaction
OQLQ (osteoporosis QoL
questionnaire) [118]
Interviewer 30, short version:10 3 Domains: physical function, emotional function,
ADL
OFDQ (Osteoporosis Functional
Disability Questionnaire) [119]
Interviewer 69 6 Domains: general health, back pain, confidence,
ADL, socialization, depression
OPTQoL (osteoporosis-targeted
QoL questionnaire) [120]
Interviewer 33 3 Domains: physical activity, adaptations, fears
ADL activities of daily living, IADL instrumental activities of daily living
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‘‘need to stay independent’’ and maintain self-efficacy; any
perceived threat to these ideals has a strong negative
impact on QoL [85, 130].
Yet these drivers (domains) remain difficult to quantify:
• The lack of energy (anergia) experienced by some older
adults is a complex phenomenon that is often associ-
ated with underlying chronic conditions, such as
inflammation, undernutrition, pain, masked depression,
and cognitive and functional decline [93]. The concept
of ‘‘mental energy’’ in itself is a three-dimensional
construct consisting of mood (transient feelings about
the presence of fatigue or energy), motivation (deter-
mination and enthusiasm), and cognition (sustained
attention and vigilance) [131].
• The physical activity domain is challenging since there is
a huge number of possible subdomains and items. In a
review of 104 patient-reported physical activity ques-
tionnaires for chronic diseases and older populations,
Williams and colleagues [99] identified 182 physical
activity (sub) domains with 1,965 associated items. They
concluded, as others have done, that it is crucial to
construct a conceptual framework for the areas and
boundaries of physical activity early on in such a project.
While the QoL instruments usually refer to the dimen-
sion of ‘‘physical function,’’ it should be considered that its
reciprocal is ‘‘disability’’ [132]—it is thus a question of
perspective. Some clinical specialities, for example, rheu-
matology and gerontology, have a historical preference for
the term ‘‘disability’’ over ‘‘physical function.’’ But if one
should adopt the language of the ICF, then one should use
‘‘disability’’ with the concept of an impairment of func-
tioning with respect to generally accepted population
standards [41].
It is clear that any new instrument would need to be
thoroughly validated in terms of its reliability and sensi-
tivity to change. This aspect of QoL instrument develop-
ment has advanced significantly in recent years with the
publication of the COSMIN guidelines, which provide
consensus-based standards for the evaluation and devel-
opment of health-related PROs [133, 134].
As part of the FDA roadmap initiative, PROMIS
(patient-reported outcomes measurement information sys-
tem) sets out to provide clinical researchers with a bank of
validated QoL modules that can be assembled for com-
puterized scoring [135]. It has defined three main compo-
nents (dimensions): physical health, mental health and
social health, with seven subcomponents and 16 domains
(e.g., pain, fatigue, physical function, negative/positive
affect, social isolation, ability to participate in social
activities). In early testing within the field of rheumatol-
ogy, these modules appear to be effective in assessing self-
reported physical functioning [132, 136].T
a
b
le
5
co
n
ti
n
u
ed
P
o
p
u
la
ti
o
n
D
ia
g
n
o
si
s
o
f
sa
rc
o
p
en
ia
/f
ra
il
ty
Q
O
L
R
es
u
lt
s
L
an
g
lo
is
et
al
.
[1
2
7
]
C
an
ad
a
n
=
8
3
(3
9
fr
ai
l
?
4
4
n
o
n
fr
ai
l)
F
ra
il
ty
as
se
ss
ed
u
si
n
g
a
g
er
ia
tr
ic
ex
am
in
at
io
n
an
d
sc
o
re
d
u
si
n
g
th
e
m
o
d
ifi
ed
p
h
y
si
ca
l
p
er
fo
rm
an
ce
te
st
Q
L
S
I
F
ra
il
el
d
er
s
re
p
o
rt
ed
p
o
o
r
se
lf
-p
er
ce
p
ti
o
n
o
f
p
h
y
si
ca
l
ca
p
ac
it
y
,
co
g
n
it
io
n
,
af
fe
ct
iv
it
y
,
h
o
u
se
k
ee
p
in
g
ef
fi
ca
cy
,
an
d
p
h
y
si
ca
l
h
ea
lt
h
4
7
A
ll
st
u
d
ie
s
w
er
e
o
f
co
m
m
u
n
it
y
-d
w
el
li
n
g
in
d
iv
id
u
al
s;
al
l
st
u
d
ie
s
ex
ce
p
t
G
o
b
b
en
s
et
al
.
[1
2
6
]
w
er
e
cr
o
ss
-s
ec
ti
o
n
al
;
u
n
le
ss
st
at
ed
,
p
at
ie
n
ts
w
er
e
at
le
as
t
6
5
y
ea
rs
o
ld
fo
r
in
cl
u
si
o
n
A
L
M
ap
p
en
d
ic
u
la
r
le
an
m
as
s,
B
M
D
b
o
n
e
m
in
er
al
d
en
si
ty
,
B
P
b
o
d
il
y
p
ai
n
,
D
X
A
d
u
al
-e
n
er
g
y
X
-r
ay
ab
so
rp
ti
o
m
et
ry
,
G
H
g
en
er
al
h
ea
lt
h
,
n
a
n
o
t
av
ai
la
b
le
,
P
H
p
h
y
si
ca
l
h
ea
lt
h
,
P
o
p
p
o
p
u
la
ti
o
n
,
Q
L
S
I
Q
u
al
it
y
o
f
L
if
e
S
y
st
em
ic
In
v
en
to
ry
Q
u
es
ti
o
n
n
ai
re
,
R
P
ro
le
p
h
y
si
ca
l,
V
T
v
it
al
it
y
114 R. Rizzoli et al.: Quality of Life in Sarcopenia and Frailty
123
There are frequent calls from members of the research
community for an approach that uses utility weighting. The
value of a measure that can be integrated over time to
obtain an overall figure for disability (or disutility) is well
known. Possibly a time trade-off study such as that used by
Salkeld and colleagues [97] would be applicable in this
population. This approach will be helpful to evaluate the
burden of the disease.
In any construct that purports to assess QoL in sarco-
penia it will be important to try to understand the effect
size of disability on overall QoL. Sarcopenia may only lead
to poor QoL in a context of disability, and this will be vital
to dissect. Frailty is always associated with disability and,
thus, carries an inherently greater risk of poor QoL.
An ideal QoL construct in sarcopenia would assess the
physical aspects of the musculoskeletal domain and give an
even-handed balance to the other factors affecting QoL. It is
anticipated that, as a patient-reported measure, it would
complement the objective assessments of physical perfor-
mance [137]. It would include the functionality of articula-
tions and the impact of bone health as well as an assessment of
pain, fatigue, and the emotional aspects and other non-health-
related dimensions of the conditions. It should also take into
account any change in weight and perhaps certain behavioral
changes to help explain longitudinal differences. A com-
prehensive construct, coupled with multivariate analysis
models, would provide the most useful outcome trajectories.
Conclusions on Goals and Challenges of QoL
Assessment in Frailty and Sarcopenia
With the publication of three, fairly similar consensus
definitions for sarcopenia, important progress has been
made; and it is expected that future research will build on
this new foundation. It may be hoped that a consensus
definition for frailty might soon also see the light of day,
for it is clear that medical research and practice advances
by the definition of formal criteria that define clinical
syndromes. Examples of this in the past include Alzhei-
mer’s disease and osteoporosis [138], recognized patho-
logical conditions that were once just syndromes.
While the two conditions, sarcopenia and frailty, are
closely related, it may be seen that sarcopenia is a key
component of frailty. This is shown schematically in
Fig. 2. Both conditions may be considered as being geri-
atric syndromes with multifactorial causes, both increasing
the risk of serious disability with a consequent and strong
impact on health-care costs. It is therefore critical to halt or
slow down this progression. Proactive steps should there-
fore be taken early following diagnosis.
Efforts must now be made so that the consensus defi-
nitions are widely recognized and refined accordingly. The
application of terms, measurement techniques, and cutoffs
must be used consistently.
An important question will be, is it necessary to develop
from scratch specific QoL instruments for sarcopenia and
frailty? Or are there available instruments that can be
adapted? A variety of PRO instruments have been devel-
oped for older populations as well as some relevant dis-
ease-specific instruments, so it may be that some part could
be adapted. Also to be considered are the growing number
of modules available in the PROMIS program. The SF-36
should still serve as a generic core, but its limitations are
evident.
It can be hoped that health-care providers and regulatory
agencies will recognize that these age-related conditions
invoke high personal and social costs and are suitable
Fig. 2 The domains of frailty
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targets for intervention [139]. In this regard, the European
Medicines Agency with its Geriatric Medicines Strategy
has taken initial steps for fostering the development of
geriatric medicines and incorporating geriatric aspects into
the assessment at authorization and postmarketing sur-
veillance of approved drugs [140]. The European com-
mission, via the innovation partnership on active and
healthy ageing (EIP on AHA), has put a target of adding
two healthy life years to citizens by 2020 [141].
Improvements in geriatric medicine will help to make this
goal achievable.
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